Eli Lilly and Company announced new positive data from its Phase 3b LUCENT-URGE study for Omvoh, a treatment for moderately to severely active ulcerative colitis (UC). The study, which specifically focused on the impact of the treatment on bowel urgency, showed that patients experienced significant and early improvements in severity, frequency, and their ability to defer using the restroom. The results are being presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting. Key findings from the study revealed that by week 12, patients saw a 55% reduction in the daily frequency of bowel urgency episodes, with severity reduced by more than half by week 28. This is the first study in inflammatory bowel disease to formally assess these specific aspects of bowel urgency, a symptom that significantly impacts patients' quality of life. The data reinforces Omvoh's potential to help patients regain control over a debilitating aspect of their condition.